--- title: Incidence and Microbial Profiles of Periprosthetic Joint Infection After Total Knee Arthroplasty in Obese vs Non-Obese Patients nct_id: NCT07398742 overall_status: COMPLETED sponsor: Bispebjerg Hospital study_type: OBSERVATIONAL primary_condition: Knee Arthropathy countries: Denmark canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07398742.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07398742" ct_last_update_post_date: 2026-02-10 last_seen_at: "2026-05-12T07:03:58.285Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Incidence and Microbial Profiles of Periprosthetic Joint Infection After Total Knee Arthroplasty in Obese vs Non-Obese Patients **NCT ID:** [NCT07398742](https://clinicaltrials.gov/study/NCT07398742) ## Key Facts - **Status:** COMPLETED - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 101299 - **Lead Sponsor:** Bispebjerg Hospital - **Conditions:** Knee Arthropathy, PJI - **Start Date:** 2025-01-01 - **Completion Date:** 2025-11-25 - **CT.gov Last Update:** 2026-02-10 ## Brief Summary Importance: After a primary total knee arthroplasty (TKA), we anticipate that obese individuals are more likely to experience a of periprosthetic joint infection (PJI). Knowing the microbial profile in obese patients can potentially help in choosing the proper prophylactic measures for this group as well as tailoring the empirical antibiotics in relation to PJI in obese patients. Objective: To compare incidence of PJI revisions within 2 years after TKA in obese vs non-obese OA patients. Secondarily: To compare microbial profiles of infections in these groups in two time windows: early (≤90 days) vs late (91-730 days) and incidence of revisions due to all causes within 2 years.Design and Setting: We will include patients having primary knee arthroplasty using Danish national registers. Patients will be stratified into anthropometric groups, referred to as exposed and unexposed to obesity, based on their baseline Body Mass Index (BMI). Participants included in the analysis population will be followed up for 2 years, until first revision, death or migration whichever comes first. Participants: We will include adult patients with available weight and height data with primary/idiopathic or secondary (due to meniscus or cruciate ligament lesion) OA who received primary TKA in the period from 2011-01-01 and 2021-02-28. Patients will be identified from the Danish knee arthroplasty register. Exposure and Comparator: The cohort will be divided into obese (exposed), defined as body mass index (BMI) ≥ 30 kg/m2; and non-obese (unexposed), defined as BMI \< 30 kg/m2. Main Outcomes and Measures: The primary outcome will be revision due to prosthetic joint infection (PJI) within 730 days following TKA. Secondary endpoints will then be to examine revision due to all causes within 730 days following TKA and type of microbial infection between obese and non-obese in the first 90 days and the period from 91 days to 730 days following TKA. Planned Statistical Analyses: We will use descriptive statistics to summarize the baseline characteristics of the two groups. Hazard ratios with corresponding two-sided 95% confidence intervals (95%CIs) for experiencing the outcome will be estimated using a Cox proportional hazards regression model. We will fit both unadjusted (crude) model and a propensity score adjusted model calculated based on age, sex, highest completed education, household income, comedications, and Elixhauser Comorbidity Measure (ECM), all collected up to the day of surgery. Stratified analyses will categorize PJI cases by bacterial infection and compare crude proportions between groups based on the absolute risk difference with 95% confidence intervals. Ethical Considerations and Registration: The study and its statistical analysis plan will be registered in clinicaltrials.org prior to conducting the study. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Adults with available BMI data recieved knee arthroplasty due to osteoarthritis Exclusion Criteria: \- ``` ## Arms - **Patients with obesity** — Patients with body mass index of 30 or more - **Patients without obesity** — Patients with body mass index less than 30 ## Primary Outcomes - **Incidence Periprosthetic joint infection** _(time frame: 2 years)_ — PJI: our definition of PJI is adapted from The European Bone and Joint Infection Society (EBJIS) criteria as at least one of the following: A. Danish Knee Arthroplasty Register-registered revision surgery due to infection. B. At least 2 deep-tissue samples of phenotypically indistinguishable bacteria isolated from at least 3 deep-tissue samples C. One or more positive intraoperative samples from a closed fluid aspirate AND a biopsy (fluid AND tissue) of phenotypically indistinguishable bacteria isolated. ## Secondary Outcomes - **Incidence of Revision due to all causes** _(time frame: 2 years)_ - **Proportions Microbiological profiles in periprosthetic infection** _(time frame: 90 days)_ - **Proportions of Microbiological profiles in periprosthetic infection** _(time frame: 91 days to 2 years)_ ## Locations (1) - Department of Orthopedic surgery and traumatology, Bispebjerg Hospital, Copenhagen, Denmark, Copenhagen NV, Denmark ## Recent Field Changes (last 30 days) - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.department of orthopedic surgery and traumatology, bispebjerg hospital, copenhagen, denmark|copenhagen nv||denmark` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07398742.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07398742* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*